Drug Trial Radar · NCT05870540
BPL-003 Efficacy and Safety in Treatment Resistant Depression
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
196
Actual
Start
Sep 14, 2023
Primary completion
Mar 28, 2025
Study completion Jul 3, 2025
Sponsor
- Lead sponsor
- Beckley Psytech LimitedIndustry
- Sponsor type
- Industry
- First posted
- May 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 study randomized, quadruple-masked, multi-center trial with an open-label extension (OLE), designed to investigate the efficacy and safety of BPL-003 in patients with treatment resistant depression (TRD).
Conditions
- Treatment Resistant Depression
Interventions
BPL-003Drug
A single dose administered intranasally
BPL-003Drug
A single dose administered intranasally (administered as 2 nasal sprays, 10 minutes apart)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Core: Change From Baseline in Montgomery and Asberg Depression Rating Scale (MADRS) Total Score at Day 29 (12 mg vs 0.3 mg BPL-003)Time frame: 4 weeks
- OLE: Number of Participants With Treatment-emergent Adverse Events in the OLETime frame: 8 weeks
Locations
42 sites in 6 countries. Site status is shown where the registry gives one.
UAB School of Public Health, Department of Health Behavior
Birmingham, Alabama
Woodland Research Northwest
Rogers, Arkansas
Kadima Neuropsychiatry Institute
San Diego, California
San Francisco Insight and Integration Center
San Francisco, California
Pacific Neuroscience Institute, Treatment and Research in Psychedelics (TRIP) Program
Santa Monica, California
Wholeness Center
Fort Collins, Colorado
Segal Trials Center for Psychedelic and Cannabis Research
Lauderhill, Florida
Emory University, Brain Health Center, Department of Psychiatry and Behavioral Sciences
Atlanta, Georgia
CenExel ACMR
Atlanta, Georgia
CenExel iResearch
Decatur, Georgia
Sunstone Medical PC (Sunstone Therapies / Aquilino Cancer Center)
Rockville, Maryland
Boston Clinical Trials
Boston, Massachusetts
CenExel HRI
Berlin, New Jersey
New York State Psychiatric Institute
New York, New York
Portland Psychotherapy
Portland, Oregon
Insite clinical research
DeSoto, Texas
AIM Trials
Plano, Texas
Cedar Clinical Research
Draper, Utah
University of Wisconsin, Dept of Family Medicine & Community Health
Madison, Wisconsin
NeuroCentrix Research
Melbourne, Australia
Royal Melbourne Hospital, University of Melbourne
Parkville, Australia
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia
Dept. of Psychiatry and School Psychological Sciences, Monash University
Clayton, Victoria, Australia
Charité - Universitätsmedizin Berlin
Berlin, Germany
OVID Clinic, Augmented Psychotherapy
Berlin, Germany
Department of Psychiatry, University Hospital Frankfurt
Frankfurt am Main, Germany
Central Institute of Mental Health, Dept. of Molecular Neuroimaging
Mannheim, Germany
Universitätsklinik für Psychiatrie und Psychotherapie, Calwerstr. 14
Tübingen, Germany
Department of Psychiatry, UCK
Gdansk, Poland
Centrum Badań Klinicznych PI-House sp. z o.o.
Gdansk, Poland
SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi
Lodz, Poland
Klinika Inventiva
Tuszyn, Poland
Department of Pharmacology and Physiology of CNS
Warsaw, Poland
Hospital del Mar
Barcelona, Spain
Parc Sanitari Sant Joan de Deu HD Numancia
Barcelona, Spain
Hospital Clinic de Barcelona, Psychiatry and Psychology Dept.
Barcelona, Spain
Fundación de Investigación HM Hospital
Madrid, Spain
Centro de Salud Mental La Corredoria
Oviedo, Spain
Centro Salud San Juan
Salamanca, Spain
NIHR Exeter Clinical Research Facility
Exeter, United Kingdom
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.